Background: Comorbidity of Myasthenia gravis (MG) and Graves' disease (GD) in treated HIV-infected individuals has rarely been described and little study has been done on the link between HIV-related immune reconstitution and autoimmune diseases occurring post antiretroviral therapy.
Case Presentation: Here we report on a 33-year-old Chinese man with HIV infection who had been virologically suppressed since 2018. The patient was diagnosed with GD and was treated in 2020. Early in 2022, he developed fluctuating weakness and fatigue involving the bilateral extraocular muscles and limbs. With a positive neostigmine test, he was considered to have MG, but showed a poor response to oral medication. After multiple failed medication attempts, a thymectomy was finally performed to resolve his symptoms. The consecutive onset of immunological events may have partially resulted from immune reconstitution after viral control.
Conclusions: This is a rare case of HIV-related immune reconstitution-associated autoimmune disease (IRAD) with comorbidity of MG and GD which was reported initially. Cooperation with multidisciplinary teams is essential to avoid misdiagnosis and to promote the overall health of HIV-infected patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/hiv.13584 | DOI Listing |
Cureus
November 2024
Neurology, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, USA.
Myasthenia gravis (MG) is one of the most common neuromuscular disorders. It is an antibody-mediated autoimmune disease affecting the neuromuscular junction, presenting with fluctuating muscle weakness that commonly affects the ocular, bulbar, proximal, and respiratory muscles. Treating MG in the older population with preexisting comorbidities can be challenging.
View Article and Find Full Text PDFEndocrine
December 2024
Department of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine, Jilin, China.
Objectives: With the prolongation of life expectancy in patients with myasthenia gravis, the number of comorbidities is increasing. Diabetes mellitus is one of the main comorbidities faced by patients with myasthenia gravis. However, there is not enough epidemiological information on diabetes mellitus.
View Article and Find Full Text PDFFront Neurol
December 2024
Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang, Shijiazhuang, China.
Background And Purpose: Myasthenia gravis (MG) is characterized by fluctuating muscle weakness due to immune-mediated damage to acetylcholine receptors. Viral infections can exacerbate symptoms of muscle weakness, and the clinical status of patients with MG may influence the outcomes of such infections. Here, we identified factors of symptom exacerbation, severe SARS-CoV-2 infection, and pneumonia in patients with MG who are infected with SARS-CoV-2.
View Article and Find Full Text PDFNeurol Sci
December 2024
1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 74 Vas. Sophias Ave., 11528, Athens, Greece.
Background/aims: The goal of this study was to assess the clinical profile of myasthenia gravis (MG) in patients diagnosed above 65-years of age (VLOMG) and identify clinical/serological parameters associated with their MG status and prognosis.
Methods: This was a retrospective assessment of consecutive patients with VLOMG (n = 70) Demographics, clinical characteristics, medical comorbidities, the Myasthenia Gravis Foundation of America (MGFA) severity scale scores, and MGFA Post-Intervention Status (MGFA-PIS) were collected.
Results: The research population was diagnosed with MG at an average age of 73.
J Neurol Sci
November 2024
Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States.
Purpose: This retrospective cohort study describes the characteristics of patients with myasthenia gravis (MG) who developed exacerbations (MG-E) and compares their healthcare utilization (HRU) to patients who did not experience exacerbations (MG-O).
Method: De-identified data from patients who had ≥2 MG-related diagnostic code submissions were extracted from the National Veterans Affairs Health Care Network electronic health records between 1999 and 2022. Descriptive statistics, Kaplan-Meier analysis, and per-patient per-year (PPPY) HRU were used to compare the two patient groups.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!